Background: Mycoplasma genitalium is estimated to be the second most common cause of bacterial sexually transmitted infection in Europe. It is of increasing public health concern due to the rapid development of resistance to different antimicrobial classes, including the preferred first-and second-line treatments azithromycin and moxifloxacin. Thus, new antimicrobial agents are urgently needed, especially for the treatment of MDR strains.
Introduction
Mycoplasma genitalium is a sexually transmitted pathogenic bacterium, which is primarily found in the urogenital tract. 1 It is the aetiological agent of several sexually transmitted infection (STI) syndromes in men and women, including acute and chronic nongonococcal urethritis (NGU), chronic prostatitis and acute epididymitis in men 1, 2 and, in women, it is associated with an increased risk of cervicitis, pelvic inflammatory disease, endometritis and infertility, 3 as well as increased sexual transmission of HIV. 4 It is the second most common bacterial STI in Europe after Chlamydia trachomatis.
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There is increased concern about this pathogen, particularly due to the rapid development of resistance to several classes of antimicrobials, which compromises the control of this bacterial STI. 6, 7 However, as M. genitalium is extremely difficult to isolate from clinical samples, only a limited number of strains are available worldwide for antimicrobial susceptibility testing. 8 Since M. genitalium lacks a cell wall, the b-lactam antibiotics and others that target the cell wall are not effective. 9 Despite M. genitalium being susceptible to tetracyclines in vitro, the most widely used compound of this class, doxycycline, has been ineffective in eradicating the infection. 6, 9 Second-and third-generation fluoroquinolones, such as ciprofloxacin, ofloxacin and levofloxacin, also eradicate only a small proportion of infections. 6, 9 Currently, the macrolide azithromycin is the recommended first-line treatment against M. genitalium and the fourth-generation fluoroquinolone moxifloxacin (a topoisomerase II inhibitor) is used as second-line treatment when azithromycin treatment fails. 10 However, resistance to azithromycin is prevalent in many countries and recent reports have shown an increasing number of treatment failures using moxifloxacin in patients carrying macrolide-resistant strains, particularly in the Asia-Pacific region. 9, 11 Moxifloxacinresistant strains carry mutations in ParC (primarily in positions S83 or D87; M. genitalium numbering), whereas resistance does not appear to be associated with mutations in GyrA in currently circulating strains. 12 Strains with macrolide and moxifloxacin resistance are considered MDR as doxycycline is clinically ineffective, thus stressing the need for new antimicrobials.
Zoliflodacin (ETX0914 or AZD0914) is a novel spiropyrimidinetrione that arrests the cleaved gyrase complex and blocks religation of the double-strand cleaved DNA to form fused circular DNA, and thus inhibits the DNA biosynthesis leading to the accumulation of double-strand cleavages. 13, 14 Despite being a topoisomerase II inhibitor, this distinct mode of action on the DNA gyrase/topoisomerase IV complex, different from all other marketed antimicrobial compounds, gives zoliflodacin the potential to become an antimicrobial solution against M. genitalium in the future. Zoliflodacin has previously been evaluated against 11 azithromycin-and fluoroquinolone-susceptible isolates of M. genitalium with MICs of ,1 mg/L. 15 Furthermore, zoliflodacin is active against both Neisseria gonorrhoeae and C. trachomatis with the highest zoliflodacin MIC of 0.25 mg/L for gonococci in a study comprising 250 strains 14 and 0.5 mg/L for C. trachomatis among 10 strains examined. 16 Thus, if zoliflodacin had activity also against MDR strains of M. genitalium, it could have potential for syndromic management of STIs.
In this study, we evaluated the in vitro activity of zoliflodacin against a collection of M. genitalium strains with and without moxifloxacin and azithromycin resistance.
Materials and methods

Culture of Vero cells
Vero cells were propagated in Eagle's MEM (SSI Diagnostica, Hillerød, Denmark) supplemented with 2% Ultroser G (Pall Life Sciences, CergySaint-Christophe, France), 3.1% of a 2.8% sodium bicarbonate solution and 100 U/mL penicillin G.
M. genitalium strains and culture
A total of 47 M. genitalium strains were selected [ Table 1 and Table S1 (available as Supplementary data at JAC Online)]. Based on historical data, 13 strains with moxifloxacin MIC 1 mg/L (considered resistant due to their isolation from patients with a history of treatment failure) and 34 moxifloxacin-susceptible strains (MIC ,1 mg/L) were included. Twenty-three of the strains had an azithromycin MIC 16 mg/L and represented macrolide-resistant isolates. The collection comprised 12 MDR strains, defined as high MICs of both azithromycin and moxifloxacin. All M. genitalium strains were isolated from clinical samples at Statens Serum Institut by primary isolation in Vero cells 8, 17 except the M. genitalium G37
T and the M30-early originally isolated by David TaylorRobinson. The M30-early strain was acquired from the Mollicutes Collection (Gainesville, FL, USA). The strains were geographically diverse, as shown in Table S1 . Cultures were quantified by quantitative PCR 18 and stored at #80 C.
Antimicrobial susceptibility testing
A zoliflodacin stock solution of 10 mg/mL in DMSO was prepared and stored at #20 C. Stock solution and testing plates were protected from light with aluminium foil during storage, handling and the incubation period.
The MIC of zoliflodacin was determined by co-culturing of M. genitalium with Vero cells as previously described. 19 Zoliflodacin was diluted in cell culture medium and tested at concentrations ranging from 0.008 to 8 mg/L (eleven 2-fold dilutions). After 3 weeks of incubation, growth inhibition of M. genitalium was determined by a quantitative PCR assay amplifying the MgPa gene (MG191). 18 The MIC was defined as the lowest antimicrobial concentration causing 99% inhibition when compared with the mean of the three growth control wells. 19 
Sequencing of the QRDRs of gyrB and parE genes
For 31 strains representing low and high MICs of zoliflodacin, the QRDRs of the gyrB and parE genes were amplified by PCR and sequenced by Sanger sequencing (Macrogen Europe, Amsterdam, The Netherlands) using primers described previously. 20 
Statistical evaluation
MICs were compared using the Mann-Whitney test in the StatsDirect version 3.0.177 software.
Results
Zoliflodacin and historical moxifloxacin and azithromycin MIC values are shown in Table 1 and raw data for individual strains are presented in Table S1 . The MICs of zoliflodacin, moxifloxacin and azithromycin ranged from 0.125 to 4 mg/L, from 0.031 to .16 mg/L and from 0.002 to 64 mg/L, respectively. There were no significant differences between the MICs of zoliflodacin and azithromycin (P " 0.860) when comparing all strains in the collection. However, for azithromycinsusceptible strains, azithromycin had lower MICs than zoliflodacin Damião Gouveia et al.
(P , 0.0001), whereas the opposite was the case for azithromycinresistant strains (P , 0.0001). Furthermore, 23 (48.9%) compared with potentially 1 (2.1%) of the strains were considered resistant to azithromycin and zoliflodacin (MIC " 4 mg/L), respectively. Zoliflodacin was overall significantly more potent than moxifloxacin (P " 0.009) and 13 (27.7%) strains were resistant to moxifloxacin. However, for moxifloxacin-susceptible strains, moxifloxacin was more potent than zoliflodacin with a median MIC of moxifloxacin of 0.125 mg/L compared with a median MIC of zoliflodacin of 0.5 mg/L (P , 0.0001). For the 13 moxifloxacin-resistant strains, the MICs of zoliflodacin ranged from 0.25 to 4 mg/L compared with 0.125 to 1 mg/L for the 34 moxifloxacin-susceptible strains. The median MIC, however, was 0.5 mg/L for both groups suggesting no cross-resistance to moxifloxacin (P " 0.38) ( Table 1) . Thus, the presence of parC QRDR mutations did not affect the zoliflodacin MICs.
A single M. genitalium strain (M6712) had a substantially elevated zoliflodacin MIC of 4 mg/L and was considered potentially resistant to zoliflodacin. This strain was moxifloxacin resistant with an MIC of 8 mg/L and had a ParC S83I mutation (M. genitalium numbering), but no mutations in the QRDR of gyrA. In GyrB, however, a D443N mutation (M. genitalium numbering) was identified. This mutation was the only GyrB mutation in the QRDR detected among the 31 strains where sequence was available. The sequence was found to be a mixture between WT and GyrB D443N in two different passages of the strain.
In the QRDR of parE, nucleotide substitutions were detected in strains M6286, M6257, M6604 and M6489, but, for the three first strains, the mutations were synonymous and did not result in any amino acid alterations in ParE. In M6489, however, a P446S (M. genitalium numbering) amino acid change was observed. This mutation did not appear to affect the zoliflodacin MIC significantly (MIC 1 mg/L).
Discussion
The treatment of M. genitalium is challenging because MDR strains are increasingly common. 6, 9 A meta-analysis showed a significant decrease in efficacy of 1 g of azithromycin for treatment of M. genitalium from 85% in studies conducted before 2009 to 60% in later studies. 21 Fluoroquinolone-resistant strains are becoming increasingly common worldwide, particularly in the Asia-Pacific region, 11, 22, 23 and these strains are commonly also resistant to azithromycin. With the poor clinical efficacy of doxycycline, these strains can be considered MDR, and easily accessible effective antimicrobials are lacking. At present, treatment of MDR M. genitalium infections has been mainly with pristinamycin as the third-line antimicrobial. 9, 11, 24 Pristinamycin is not registered in most countries worldwide, and needs to be procured on a special permit. However, treatment failure is also commonly seen with this antimicrobial. 24 The lack of available effective antimicrobials for treatment of M. genitalium is a threat to global public health, and new drugs are urgently needed.
In response to this need, we evaluated the antimicrobial activity of the novel spiropyrimidinetrione zoliflodacin against a collection of geographically, temporally and genetically different M. genitalium strains. Our study showed that zoliflodacin is significantly more active than moxifloxacin, particularly because of the lack of cross-resistance to moxifloxacin and azithromycin.
No breakpoint for zoliflodacin susceptibility has been defined. If strains with MICs ,1 mg/L are considered susceptible, then 41 (87%) of all the examined strains and 10 (77%) of the 13 moxifloxacin-resistant strains would be susceptible to zoliflodacin. If the breakpoint was suggested at ,2 mg/L, similar figures would be 98% and 92%, respectively. It should be noted, however, that the present collection of strains was highly enriched for MDR M. genitalium strains, and thus such figures are not generalizable.
Our data are similar to those presented by Waites et al., 15 who found similar MIC 50 (0.5 mg/L) and MIC 90 (1 mg/L) values of zoliflodacin for M. genitalium. However, the Waites et al. 15 study examined only macrolide-and moxifloxacin-susceptible isolates, and 6 of the 11 isolates were genetically identical to the G37 type strain as they were ATCC strains known to be contaminated with this strain. No cross-resistance between zoliflodacin and the third-generation fluoroquinolone levofloxacin was detected in ureaplasmas, but all 21 Mycoplasma hominis strains had high MICs (2-8 mg/L). 15 There is no evidence of cross-resistance between zoliflodacin and macrolides or tetracyclines in any of a range of species examined. [13] [14] [15] One MDR M. genitalium strain (M6712) had a zoliflodacin MIC of 4 mg/L, clearly higher than the remaining MDR strains. This strain carried a ParC S83I mutation, but, as other moxifloxacin-resistant strains with S83I mutations had zoliflodacin MICs similar to WT, the ParC mutation did not appear to be the cause of the elevated zoliflodacin MIC. M6712 also carried a GyrB D443N mutation (M. genitalium numbering), the latter in a mixture with WT sequence. Two separate passages of the strain were examined and, as judged by the chromatograms, the proportion of mutated strain varied from 20% to 50%. As the strain M6712 is unable to grow axenically, the isolate has not been single-cell cloned and consequently this heterotypic resistance may have been present even in the clinical specimen. Unfortunately, the primary clinical specimen is not available for analysis. The GyrB D443N mutation is identical to the D429N (N. gonorrhoeae numbering) first-step mutation described in N. gonorrhoeae strains subjected to in vitro selection of zoliflodacin resistance. The mutated N. gonorrhoeae strains had a 16-fold increase in zoliflodacin MIC to 2 mg/L. 25, 26 Thus, it is highly likely that the GyrB mutation is the reason for the elevated zoliflodacin MIC also in the M. genitalium M6712 strain. The M6712 isolate was obtained from an Australian STD-clinic patient, but, as other spiropyrimidinetriones have not been introduced on the market, it is unexplained how the heterotypic resistance was selected.
Zoliflodacin, intended for oral administration, seems to be a promising candidate compound for treatment of M. genitalium infections because of its high in vitro activity against this microorganism, the low frequency of resistance and the lack of crossresistance to both fluoroquinolones and macrolides. Zoliflodacin given orally also appears to have good target tissue penetration, good bioavailability and sufficiently high safety and tolerability (an oral dose ranging from 200 mg to 4 g has been shown to be well tolerated). 6, 14 Thus, it is warranted to consider further development of zoliflodacin for treatment of M. genitalium infections, as well as other STIs.
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